

Mark Frydenberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9309990/publications.pdf>

Version: 2024-02-01

90
papers

6,253
citations

109311

35
h-index

71682

76
g-index

92
all docs

92
docs citations

92
times ranked

7773
citing authors

#	ARTICLE	IF	CITATIONS
1	Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. <i>Lancet, The</i> , 2020, 395, 1208-1216.	13.7	1,108
2	Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 121-131.	27.0	982
3	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , 2018, 73, 178-211.	1.9	488
4	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020, 77, 508-547.	1.9	278
5	Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	210
6	Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5 2020, 21, 1331-1340.	10.7	197
7	Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. <i>European Urology</i> , 2015, 67, 460-467.	1.9	190
8	Sepsis and "superbugs": should we favour the transperineal over the transrectal approach for prostate biopsy?. <i>BJU International</i> , 2014, 114, 384-388.	2.5	187
9	Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories. <i>Nature Communications</i> , 2017, 8, 13671.	12.8	182
10	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer – An International Collaborative Multistakeholder Effort. <i>European Urology</i> , 2020, 77, 223-250.	1.9	132
11	Investigations with FDG-PET Scanning in Prostate Cancer Show Limited Value for Clinical Practice. <i>Acta Oncol</i> , 2002, 41, 425-429.	1.8	115
12	Patient-derived Xenografts Reveal that Intraductal Carcinoma of the Prostate Is a Prominent Pathology in BRCA2 Mutation Carriers with Prostate Cancer and Correlates with Poor Prognosis. <i>European Urology</i> , 2015, 67, 496-503.	1.9	112
13	Robotic Assisted Radical Cystectomy vs Open Radical Cystectomy: Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2019, 201, 715-720.	0.4	103
14	The Metaplastic Effects of Estrogen on Mouse Prostate Epithelium: Proliferation of Cells with Basal Cell Phenotype. <i>Endocrinology</i> , 2001, 142, 2443-2450.	2.8	92
15	Trajectories of quality of life, life satisfaction, and psychological adjustment after prostate cancer. <i>Psycho-Oncology</i> , 2017, 26, 1576-1585.	2.3	91
16	A preclinical xenograft model of prostate cancer using human tumors. <i>Nature Protocols</i> , 2013, 8, 836-848.	12.0	90
17	Laparoscopic and robot-assisted vs open radical prostatectomy for the treatment of localized prostate cancer: a Cochrane systematic review. <i>BJU International</i> , 2018, 121, 845-853.	2.5	88
18	Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories. <i>European Urology</i> , 2017, 72, 492-495.	1.9	81

#	ARTICLE	IF	CITATIONS
19	Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. <i>European Urology</i> , 2018, 74, 562-572.	1.9	80
20	Enduring epigenetic landmarks define the cancer microenvironment. <i>Genome Research</i> , 2018, 28, 625-638.	5.5	74
21	Detection and localisation of primary prostate cancer using ⁶⁸ gallium prostate-specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology. <i>BJU International</i> , 2020, 126, 83-90.	2.5	69
22	Semantics in active surveillance for men with localized prostate cancer – results of a modified Delphi consensus procedure. <i>Nature Reviews Urology</i> , 2017, 14, 312-322.	3.8	65
23	The Prostate Cancer Registry: monitoring patterns and quality of care for men diagnosed with prostate cancer. <i>BJU International</i> , 2013, 111, E158-66.	2.5	61
24	Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. <i>European Urology</i> , 2019, 75, 523-531.	1.9	58
25	New Challenges in Psycho-Oncology Research III: A systematic review of psychological interventions for prostate cancer survivors and their partners: clinical and research implications. <i>Psycho-Oncology</i> , 2017, 26, 873-913.	2.3	55
26	Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial. <i>International Journal of Cancer</i> , 2020, 146, 161-168.	5.1	54
27	Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial. <i>European Urology</i> , 2021, 79, 413-418.	1.9	52
28	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 115-141.	1.9	51
29	A pro-tumorigenic loop at the human prostate tumour interface orchestrated by oestrogen, CXCL12 and mast cell recruitment. <i>Journal of Pathology</i> , 2014, 234, 86-98.	4.5	47
30	Androgen deprivation therapy complications. <i>Endocrine-Related Cancer</i> , 2014, 21, T119-T129.	3.1	43
31	Transperineal biopsy prostate cancer detection in first biopsy and repeat biopsy after negative transrectal ultrasound-guided biopsy: the Victorian Transperineal Biopsy Collaboration experience. <i>BJU International</i> , 2015, 116, 568-576.	2.5	42
32	Holmium Laser Enucleation of the Prostate: Comparison of Immediate Postoperative Outcomes in Patients with and without Antithrombotic Therapy. <i>Current Urology</i> , 2013, 7, 28-33.	0.6	40
33	Effects of Testosterone Plus Medroxyprogesterone Acetate on Semen Quality, Reproductive Hormones, and Germ Cell Populations in Normal Young Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 546-556.	3.6	40
34	Intraductal carcinoma of the prostate can evade androgen deprivation, with emergence of castrate-tolerant cells. <i>BJU International</i> , 2018, 121, 971-978.	2.5	39
35	Predictors of depression, anxiety and quality of life in patients with prostate cancer receiving androgen deprivation therapy. <i>Psycho-Oncology</i> , 2013, 22, 2169-2176.	2.3	36
36	Prostate cancer survivorship essentials framework: guidelines for practitioners. <i>BJU International</i> , 2021, 128, 18-29.	2.5	35

#	ARTICLE	IF	CITATIONS
37	The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. <i>Nature Communications</i> , 2021, 12, 5049.	12.8	33
38	Establishment of primary patient-derived xenografts of palliative TURP specimens to study castrate-resistant prostate cancer. <i>Prostate</i> , 2015, 75, 1475-1483.	2.3	31
39	High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids. <i>SLAS Discovery</i> , 2021, 26, 1107-1124.	2.7	30
40	Enhancing active surveillance of prostate cancer: the potential of exercise medicine. <i>Nature Reviews Urology</i> , 2016, 13, 258-265.	3.8	28
41	Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. <i>European Urology</i> , 2021, 80, 275-279.	1.9	28
42	Knowing what's growing: Why ductal and intraductal prostate cancer matter. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	27
43	The Metaplastic Effects of Estrogen on Mouse Prostate Epithelium: Proliferation of Cells with Basal Cell Phenotype. <i>Endocrinology</i> , 2001, 142, 2443-2450.	2.8	27
44	Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance Initiative. <i>European Urology Oncology</i> , 2020, 3, 80-91.	5.4	24
45	A feasibility and acceptability study of an adaptation of the Mindful Self-Compassion program for adult cancer patients. <i>Palliative and Supportive Care</i> , 2020, 18, 130-140.	1.0	20
46	Obesity does not promote tumorigenesis of localized patient-derived prostate cancer xenografts. <i>Oncotarget</i> , 2016, 7, 47650-47662.	1.8	18
47	Development of Indicators to Assess Quality of Care for Prostate Cancer. <i>European Urology Focus</i> , 2018, 4, 57-63.	3.1	17
48	Alterations in the methylome of the stromal tumour microenvironment signal the presence and severity of prostate cancer. <i>Clinical Epigenetics</i> , 2020, 12, 48.	4.1	17
49	Impact of branding on public awareness of healthcare-related governing bodies: a pilot study of the Urological Society of Australia and New Zealand brand. <i>BJU International</i> , 2016, 118, 23-29.	2.5	16
50	Diagnostic and treatment factors associated with poor survival from prostate cancer are differentially distributed between regional and metropolitan Victoria, Australia. <i>BMC Urology</i> , 2016, 16, 54.	1.4	16
51	Work after prostate cancer: a systematic review. <i>Journal of Cancer Survivorship</i> , 2019, 13, 282-291.	2.9	15
52	Combined Utility of 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Predicting Prostate Biopsy Pathology. <i>European Urology Oncology</i> , 2022, 5, 314-320.	5.4	15
53	Can exercise delay transition to active therapy in men with low-grade prostate cancer? A multicentre randomised controlled trial. <i>BMJ Open</i> , 2018, 8, e022331.	1.9	14
54	Contemporary consumer perspectives on prostate cancer survivorship: Fifty voices. <i>Psycho-Oncology</i> , 2020, 29, 557-563.	2.3	13

#	ARTICLE	IF	CITATIONS
55	Ductal variant prostate carcinoma is associated with a significantly shorter metastasis-free survival. <i>European Journal of Cancer</i> , 2021, 148, 440-450.	2.8	13
56	Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer. <i>Prostate</i> , 2019, 79, 1326-1337.	2.3	12
57	⁶⁸ Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography Maximum Standardized Uptake Value as a Predictor of Gleason Pattern 4 and Pathological Upgrading in Intermediate-Risk Prostate Cancer. <i>Journal of Urology</i> , 2022, 207, 341-349.	0.4	12
58	Patterns of care for prostate cancer treatment and improving outcomes “ are national registries the answer?. <i>BJU International</i> , 2021, 128 Suppl 1, 6-8.	2.5	11
59	High ductal proportion predicts biochemical recurrence in prostatic ductal adenocarcinoma. <i>BJU International</i> , 2019, 124, 907-909.	2.5	10
60	Prostate cancer screening in Primary Health Care: the current state of affairs. SpringerPlus, 2015, 4, 78.	1.2	9
61	Radical prostatectomy: what do the patients really think of surgery?. <i>Medical Journal of Australia</i> , 1998, 168, 477-478.	1.7	7
62	Long-term experience of residual symptoms following treatment for localized prostate cancer: An Australian sample. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2007, 3, 199-206.	1.1	7
63	National nephrectomy registries: Reviewing the need for population-based data. <i>Korean Journal of Urology</i> , 2015, 56, 607.	1.2	7
64	Age Related Differences in Responsiveness to Sildenafil and Tamsulosin are due to Myogenic Smooth Muscle Tone in the Human Prostate. <i>Scientific Reports</i> , 2017, 7, 10150.	3.3	7
65	Trends in urologic oncology clinical practice and medical education under COVID-19 pandemic: An international survey of senior clinical and academic urologists. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 929.e1-929.e10.	1.6	7
66	Can Exercise Adaptations Be Maintained in Men with Prostate Cancer Following Supervised Programmes? Implications to the COVID-19 Landscape of Urology and Clinical Exercise. <i>European Urology Open Science</i> , 2020, 21, 47-50.	0.4	7
67	How Does Age Affect Urinary Continence following Robot-Assisted Radical Prostatectomy? A Prospective Multi-Institutional Study Using Independently Collected, Validated Questionnaires. <i>Journal of Urology</i> , 2022, 207, 1048-1056.	0.4	7
68	Nephron-sparing surgery for small incidental renal cell carcinoma. <i>ANZ Journal of Surgery</i> , 2001, 71, 349-353.	0.7	6
69	An integrated multicomponent care model for men affected by prostate cancer: A feasibility study of TrueNTH Australia. <i>Psycho-Oncology</i> , 2021, 30, 1544-1554.	2.3	6
70	The role of open radical nephrectomy in contemporary management of renal cell carcinoma. <i>Translational Andrology and Urology</i> , 2020, 9, 3123-3139.	1.4	6
71	MANAGEMENT OF SUPERFICIAL BLADDER CANCER IN VICTORIA: 1990 AND 1995. <i>ANZ Journal of Surgery</i> , 2005, 75, 270-274.	0.7	5
72	Early Androgen Deprivation Therapy Improves Survival, But How Do We Determine in Whom?. <i>European Urology</i> , 2018, 73, 519-520.	1.9	5

#	ARTICLE	IF	CITATIONS
73	Oxytocin receptor antagonists as a novel pharmacological agent for reducing smooth muscle tone in the human prostate. <i>Scientific Reports</i> , 2021, 11, 6352.	3.3	5
74	â€Painâ€free TRUS Bâ€™: a phase 3 doubleâ€blind placeboâ€controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonographyâ€guided prostate biopsy (ANZUP 1501). <i>BJU International</i> , 2022, 129, 591-600.	2.5	5
75	PSA testing for men at average risk of prostate cancer. <i>Public Health Research and Practice</i> , 2017, 27, .	1.5	5
76	Neuroendocrine cells in prostate cancer correlate with poor outcomes: A systematic review and metaâ€analysis.. <i>BJU International</i> , 2021, , .	2.5	5
77	Reliability of negative multiparametric <scp>MRI</scp> of the prostate: can we avoid the biopsy? Not yet!. <i>BJU International</i> , 2017, 119, E9-E10.	2.5	4
78	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 6-11.	1.9	4
79	Quality of life considerations in the treatment of metastatic hormone-sensitive prostate cancer. <i>Lancet Oncology</i> , The, 2019, 20, 1469-1471.	10.7	3
80	Predictors of erectile dysfunction after transperineal template prostate biopsy. <i>Investigative and Clinical Urology</i> , 2021, 62, 159.	2.0	3
81	Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?. <i>Investigative and Clinical Urology</i> , 2021, 62, 650.	2.0	3
82	Diagnosing prostate cancer - what GPs need to know. <i>Australian Family Physician</i> , 2007, 36, 345-7.	0.5	3
83	Monitoring cardiovascular health in men with prostate cancer treated with androgen deprivation therapy. <i>International Journal of Urological Nursing</i> , 2012, 6, 35-41.	0.2	2
84	Avoiding biopsy in men with <scp>PIâ€CRADS</scp> scores 1 and 2 on multiparametric <scp>MRI</scp> of the prostate, ready for prime time?. <i>BJU International</i> , 2019, 124, 715-716.	2.5	2
85	Care beyond prostate cancerâ€™improving patient outcomes. <i>Nature Reviews Urology</i> , 2014, 11, 669-671.	3.8	1
86	68Ga-PSMA-PET screening and transponder-guided salvage radiotherapy to the prostate bed alone for biochemical recurrence following prostatectomy: interim outcomes of a phase II trial. <i>World Journal of Urology</i> , 2021, 39, 4117-4125.	2.2	1
87	Selfâ€reported lack of energy or feeling depressed 12â€months after treatment in men diagnosed with prostate cancer within a populationâ€based registry. <i>Psycho-Oncology</i> , 2021, , .	2.3	1
88	Re: 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2019, 76, 405.	1.9	0
89	Editorial Comment. <i>Journal of Urology</i> , 2019, 202, 1247-1247.	0.4	0
90	PSA testing. <i>Australian Family Physician</i> , 2003, 32, 396.	0.5	0